Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs BIO-TECHNE Corp — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $61.81 (market cap $79.91B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 7.1× BIO-TECHNE Corp's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.19%). Which is the better fit depends on your goals.
| MDLZ | TECH | |
|---|---|---|
Market Cap | $79.91B | $11.24B |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $72.29 |
52-Week Low | $51.51 | $43.31 |
Enterprise Value | $100.25B | $11.32B |
Dividend Yield | 3.19% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MDLZ trades at $62.61, down 0.22% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. Recent Q2 2026 earnings beat estimates with EPS of $0.73 versus $0.68 expected, driven by 2.2% organic revenue growth. The company raised its 2026 organic sales outlook, supported by strength in emerging markets and improved execution in North America. Cash flow from operations remains robust at $4.5 billion in 2025, though net income margin dipped to 6.36% from higher costs.
Outlook is positive with a consensus price target of $70.50, implying 12.6% upside, and 76% of analysts rate it a buy. Risks include reliance on international sales exposure to currency fluctuations and competitive pressures in the snack industry. Valuation multiples like P/E of 38.25 appear elevated relative to historical norms, requiring sustained earnings growth to justify current levels.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
